AGE VERIFICATION

Please certify that you are 19 of age or older in order to access this website.

Yes, I am over 19 No, I am under 19

Latest News/Research

Biohacking and brain development with magic mushrooms.
Press BriefResearch Summary

The Latest Promising Long COVID Treatment? Psychedelic Drugs

Psychedelic substances, including psilocybin and MDMA, may offer a promising treatment option for the psychological symptoms of long COVID. These substances have demonstrated efficacy in treating mental health conditions by promoting neuroplasticity and therapeutic breakthroughs. Further research is needed to confirm their safety, efficacy, and long-term effects in treating long COVID-related symptoms.
by The ShrumLane Team April 18, 2023
Growing magic mushrooms hallucinogenic psilocybe cubensis
Press BriefResearch Summary

Research As It Happens: Testing psilocybin-assisted psychotherapy for treatment of co-occurring major depression and alcohol use disorder

A clinical trial at the Centre for Addiction and Mental Health is investigating the potential of psilocybin-assisted psychotherapy for treating co-occurring major depression and alcohol use disorder (AUD). The groundbreaking study aims to explore the safety, feasibility, and efficacy of this novel approach to address both disorders simultaneously.
by The ShrumLane Team March 28, 2023
Mycelium of psilocybin psychedelic mushrooms Golden Teacher. Macro view, close-up. Micro-dosing concept. Micro growing of raw Psilocybe Cubensis mushrooms on white background.
Research Summary

Psilocybin therapy for depression. A good trip?

The paper "The Efficacy of Psilocybin in the Treatment of Depression and Anxiety: A Meta-Analysis" presents a comprehensive review of 12 randomized controlled trials, demonstrating that psilocybin, a compound found in certain species of mushrooms, leads to significant reductions in depression and anxiety symptoms compared to placebo or standard care. The improvements were observed in both short- and medium-term periods, with additional positive impacts on quality of life and functioning, and only mild, transient adverse effects reported. Despite some study limitations, the results provide strong support for psilocybin's potential as a valuable treatment option for depression and anxiety, although further research is needed to optimize dosage, administration, and therapeutic settings, as well as to investigate potential synergistic effects with other therapeutic modalities.
by The ShrumLane Team March 14, 2023
Psychedelic psilocybin mushrooms Golden Teacher, top view, close-up. Psilocybe Cubensis raw mushrooms isolated on black background. Micro-dosing concept.
Research Summary

The Promise and Perils of Psychedelics

The New England Journal of Medicine's podcast episode, "The Promise and Perils of Psychedelics," delves into the burgeoning interest in psychedelic research for mental health treatment, examining both the potential therapeutic benefits and risks associated with these substances. The episode traces the history of psychedelics, discusses their efficacy in treating conditions such as depression, anxiety, and PTSD, and explores their ability to foster personal growth, creativity, and spiritual experiences. However, it also addresses the potential risks, such as adverse reactions and addiction, as well as the legal, regulatory, and ethical challenges surrounding their use. In providing a comprehensive and balanced overview, the podcast emphasizes the need for further research and the development of standardized treatment protocols to ensure the safe and effective integration of psychedelics into mainstream mental health care.
by The ShrumLane Team February 24, 2023
12-month follow-up 1 5-HT2A receptor 2 abstinence rates 1 acute effects 1 addiction 3 addiction treatment 1 advanced cancer 1 adverse effects/events/reactions 3 alcohol consumption 1 Alcohol Use Disorder (AUD) 4 alternative medications 1 alternative treatment 1 antidepressants 3 anxiety 18 athletes 1 attitudes 1 attitudes towards death 1 ayahuasca 1 bad trips 1 bipolar disorder 1 body dysmorphic disorder (BDD) 1 body mass index (BMI) 1 brain network connectivity 1 breakthrough therapy 4 cancer patients 4 clinical applications 1 clinical environment 1 clinical trial 2 clinical trials 4 clinically meaningful response 1 cluster headache 1 co-occurring disorders 1 cognitive functioning 1 cognitive-behavioral therapy (CBT) 3 commodification 1 connectedness 1 controlled trial 1 courses 1 decriminalization 1 default mode network 1 dependence 1 depression 17 depression severity 1 depressive symptoms 0 DMT 1 double-blind 5 efficacy 4 emotional challenges 1 emotional eating 1 emotional release 1 emotional well-being 1 empathy 2 end-of-life care 1 ethical implications 1 existential distress 2 food addiction 1 functioning 1 guide 2 guided trip 1 hallucinogen persisting perception disorder (HPPD) 1 hallucinogenic mushrooms 1 Hamilton Depression Rating Scale 2 harm potential 1 harm reduction 1 headache frequency 1 headache intensity 1 healing process 1 heavy drinking days 1 history 1 implementing insights 1 improved mood 1 indigenous cultures 1 individual differences 1 individual factors 1 interconnectedness 1 international survey 0 introspection 1 Jamaica 1 lasting antidepressant effect 1 legal barriers 1 legal hurdles 1 legalization 1 life-threatening cancer 1 limitations 3 long COVID 1 long-term effects 1 low-dose pulse regimen 1 LSD 3 magic mushrooms 7 mainstream healthcare 1 major depression 1 major depression disorder 1 major depressive disorder (MDD) 7 manic episodes 0 manic symptoms 1 MDMA 3 meaning response 1 mechanism of action 1 mental health 10 mental health treatment 2 meta-analysis 3 microdosing 2 Moms on Mushrooms 1 Montgomery-Asberg Depression Rating Scale (MADRS) 2 mood regulation 0 mycotherapy 1 Netherlands 1 neurobiological mechanisms 0 neuroplasticity 6 nonrandomized controlled trial 1 novel treatment 1 obesity 1 obsessive-compulsive disorder (OCD) 2 online community 1 openness 1 paranoia 1 participant experiences 1 performance enhancement 1 personal experience 2 personal growth 2 pharmacotherapy 2 physical pain 1 physiological responses 1 pilot study 1 placebo-controlled 4 post-traumatic stress disorder (PTSD) 7 potential risks 1 psilocybin 25 Psilocybin therapy 2 psilocybin truffle retreat 1 psilocybin-assisted psychotherapy 1 psilocybin-assisted therapy 16 psychedelic integration 1 psychedelic research 1 psychedelic-assisted therapy 3 psychedelics 6 psychiatric disorders 1 psychiatric illness 1 psycho-social-spiritual well-being 2 psychological distress 1 psychological flexibility 1 psychological growth 1 psychological responses 1 psychotherapists 1 psychotherapy 6 qualitative analysis 2 quality of life 7 randomized 1 randomized controlled trial 8 rapport 2 regulatory barriers/challenges 2 relationships 1 remission 1 research 2 research implications 1 resilience 1 resistance 1 retreat setting 1 risks 5 safety 8 scalable model 1 scientific research 1 self-awareness 1 self-reflection 1 self-report 0 serotonergic system 2 serotonin 2A receptors 1 serotonin agonist 1 set and setting 1 severe depression 1 side effects 3 single-dose 1 social challenges 1 spiritual experiences 3 spiritual well-being 2 standardized treatment protocols 1 stress 1 stress-induced weight gain 1 structured support 1 substance 1 substance use disorders 2 suicidality 1 survey 1 symptom reduction 1 systematic review 1 thematic analysis 1 therapeutic outcomes 2 therapeutic potential/benefits 7 therapeutic relationship 2 therapeutic settings/environment 2 toxicity 1 training 1 transformative experiences 2 treatment 1 treatment efficacy 3 treatment option 1 treatment-resistant depression 4 vulnerable populations 1 web-based questionnaire 0 wellness 1 Yale-Brown Obsessive Compulsive Scale 1
Home
Shop
0 Wishlist
Search
More
More